Historical discourse on the development of the live attenuated tetravalent dengue vaccine candidate TV003/TV005
AP Durbin - Current opinion in virology, 2020 - Elsevier
Dengue is the most important arboviral disease world-wide with an estimated 400 million
annual infections. Dengvaxia™ is a live attenuated tetravalent vaccine recently licensed for
dengue seropositive individuals aged 9–45 years. There is great need for a dengue vaccine
that could be given to dengue-naïve individuals and very young children. To that end, the
US NIH developed a live attenuated tetravalent dengue vaccine using an iterative approach
evaluating the safety, infectivity, and immunogenicity of different candidates. This approach …
annual infections. Dengvaxia™ is a live attenuated tetravalent vaccine recently licensed for
dengue seropositive individuals aged 9–45 years. There is great need for a dengue vaccine
that could be given to dengue-naïve individuals and very young children. To that end, the
US NIH developed a live attenuated tetravalent dengue vaccine using an iterative approach
evaluating the safety, infectivity, and immunogenicity of different candidates. This approach …